BG103185A - 7 alpha -(epsilon -aminoalkyl)-estratrines, method for their preparation, pharmaceutical preparations containing them and their application for the preparation of medicamentous forms - Google Patents
7 alpha -(epsilon -aminoalkyl)-estratrines, method for their preparation, pharmaceutical preparations containing them and their application for the preparation of medicamentous formsInfo
- Publication number
- BG103185A BG103185A BG103185A BG10318599A BG103185A BG 103185 A BG103185 A BG 103185A BG 103185 A BG103185 A BG 103185A BG 10318599 A BG10318599 A BG 10318599A BG 103185 A BG103185 A BG 103185A
- Authority
- BG
- Bulgaria
- Prior art keywords
- residue
- atom
- hydrogen atom
- group
- mean
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The compoundns can be applied for the preparation ofmedicamentous forms designed for tumour and hormonal therapy. Theyshow very strong antistrogenous effect. Part of them are pureantiestrogens, and another part have partial estrogenous effect.The substituted 7-( -aminoalkyl)-estratrines have the formulawhere the side chain SK means a residue with the formula- -(CH2)m- -N- -CH- -(CH2)n--(CH2)3--EA B Dwhere m has the value of 4, 5 or 6, n - 0, 1 or 2, x - 0, 1 or 2,A means hydrogen atom or C1-5-alkyl group, B and D are always ahydrogen atom, or C1-5-alkyl group, B & D are always a hydrogenatom, or A & B together mean alkylene group --(CH2)p--c, p iw 2,34or 5 and D is hydrogen atom, or A & D together mean alkylene group-(CH2)q-- c, q is 2, 3 or 4 and B means hydrogen atom and E isunsubstituted or one or five times fluorinated ethyl residue, orthe end substitutent --(CH2)-2-E-- of the side chain is optionallysubstituted by a substituted aryl and heteroaryl residue which isbound directly or by means of mono- di- or trimethylene group tothe sulphur atom, R3 means hydrogen atom, carbon residue with upto 8 carbon atoms or residue with the formulaR3'-C(O)-,where R3' is hydrogen or carbon atom with up to 8 carbon atoms oris phenyl residue, R11 is hydrogen, halogen atom or onenitrooxygroup -O-NO2, R14, R15, R16 & R16 always mean hydrgoenatom or R14 & R15 mean additional bond or methylene bridge, or R15means methylene group and R15 means hydrogen atom, or R15 & R15are alway a methylene group, or R15 and R16 together formmethylene bridge, or R16 or R16 means halgen atom or R16 togethermean methylidene group and the customary substitutents R14m R15,R15, R16 and R16 are always hydrogen atom, R17' means hydrogenatom in - or - position means C1-5-alkyl, C2-5-alkylene orC2-5-alkynyl group or is trifluoromethyl group and R17" ishydrogen atom or residue with formulaR17''' --C(O)--in which R17''' is hydrogen atom or carbon residue with up to 8carbon atoms, or when R17' is in - position, R17', together withR14 form ethanol bridge provided that A & B simultaneously do notmean -(CH2)p or A & D togehter do not mean -(CH2)q, at least onesubstituent of R11, R14, R15, R16 & R16 is not a hydrogen atom.The invention also relates to the physiologically aceptableadjunctive salts of the compounds with organic and inorganicacids.42 claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19635525A DE19635525A1 (en) | 1996-08-20 | 1996-08-20 | New 7-alpha-(xi-aminoalkyl)- oestratriene derivatives |
| PCT/EP1997/004517 WO1998007740A1 (en) | 1996-08-20 | 1997-08-20 | 7α-(κ-AMINOALKYL)ESTRATRIENES, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 7α-(κ-AMINOALKYL)ESTRATRIENES AND THEIR USE FOR PREPARING MEDICAMENTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG103185A true BG103185A (en) | 1999-11-30 |
| BG62972B1 BG62972B1 (en) | 2000-12-29 |
Family
ID=7804367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG103185A BG62972B1 (en) | 1996-08-20 | 1999-02-16 | 7 alpha-(epsilon-aminoalkyl)-estratrines, method for their preparation, pharmaceutical preparations containing them and their application for the preparation of medicamentous forms |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0920441B1 (en) |
| JP (1) | JP2001503024A (en) |
| KR (1) | KR20000068261A (en) |
| CN (1) | CN1231670A (en) |
| AR (1) | AR009278A1 (en) |
| AT (1) | ATE231882T1 (en) |
| AU (1) | AU728843B2 (en) |
| BG (1) | BG62972B1 (en) |
| BR (1) | BR9711328A (en) |
| CA (1) | CA2263708A1 (en) |
| CZ (1) | CZ57999A3 (en) |
| DE (2) | DE19635525A1 (en) |
| DK (1) | DK0920441T3 (en) |
| EA (1) | EA001577B1 (en) |
| EE (1) | EE04021B1 (en) |
| ES (1) | ES2191857T3 (en) |
| HU (1) | HUP9903106A3 (en) |
| IL (1) | IL128601A (en) |
| IS (1) | IS4976A (en) |
| NO (1) | NO315655B1 (en) |
| NZ (1) | NZ334277A (en) |
| PL (1) | PL186309B1 (en) |
| PT (1) | PT920441E (en) |
| SK (1) | SK18899A3 (en) |
| TR (1) | TR199900432T2 (en) |
| TW (1) | TW552267B (en) |
| UA (1) | UA50792C2 (en) |
| WO (1) | WO1998007740A1 (en) |
| ZA (1) | ZA977482B (en) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR015500A1 (en) * | 1997-12-23 | 2001-05-02 | Schering Ag | 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, PROCEDURE FOR PREPARING PHARMACEUTICAL PREPARATIONS THAT CONTAIN SUCH 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, AS WELL AS USED IN THE PREPARATION OF MEDICINES. |
| US6054446A (en) * | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6548491B2 (en) | 1997-12-24 | 2003-04-15 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6503896B1 (en) | 1997-12-24 | 2003-01-07 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| DE19807791A1 (en) * | 1998-02-19 | 1999-08-26 | Schering Ag | Combination preparation of estrogen with 7-aminoalkyl-estratriene antiestrogen, useful in hormone replacement therapy, e.g. for treatment osteoporosis, Alzheimer's disease and hot flushes |
| DE19833786A1 (en) * | 1998-07-18 | 2000-01-20 | Schering Ag | New diphenyl-benzocycloheptene derivatives, are tissue-selective estrogens and antiestrogens useful e.g. for treating osteoporosis or hormone-dependent tumors or in hormone replacement therapy |
| DE19842123C1 (en) * | 1998-09-05 | 2000-07-13 | Schering Ag | 11beta-fluoro-7alpha- (14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl) estra-1,3,5 (10) - triene-3,17beta-diol as crystalline solvate |
| DE19906159A1 (en) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-hydroxyestratrienes as selectively active estrogens |
| AU6913700A (en) * | 1999-08-18 | 2001-03-13 | Schering Aktiengesellschaft | Piperidine and pyrrolidine derivatives displaying neuronal activity |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| DE10019171A1 (en) * | 2000-04-07 | 2001-10-18 | Schering Ag | Compositions for use as penetration enhancers in transdermal formulations for highly lipophilic active ingredients |
| AU2006202187B2 (en) * | 2001-11-27 | 2008-11-06 | Bayer Schering Pharma Aktiengesellschaft | 17alpah-alkyl-17beta-oxy-estratrienes and intermediate products for their production, uses thereof and pharmaceutical preparations |
| DE10159217A1 (en) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| WO2006015081A2 (en) * | 2004-07-27 | 2006-02-09 | Sicor, Inc. | A PROCESS FOR THE PREPARATION OF 7α-ALKYLATED 19-NORSTEROIDS |
| EP1951664A1 (en) | 2005-11-22 | 2008-08-06 | Sumitomo Chemical Company, Limited | Organic sulfur compounds and use thereof as arthropodicides |
| DE102007049630A1 (en) | 2007-10-11 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | New amide compounds used for therapy and/or prophylaxis of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy |
| DE102007023614A1 (en) | 2007-05-21 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | New amide compounds used for treatment of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy, has general formula |
| TW200904329A (en) | 2007-05-18 | 2009-02-01 | Sumitomo Chemical Co | Organic sulfur compound and its use for controlling harmful arthropod |
| JP5298631B2 (en) | 2007-05-18 | 2013-09-25 | 住友化学株式会社 | Organic sulfur compounds and their use for controlling harmful arthropods |
| JP2009001551A (en) | 2007-05-18 | 2009-01-08 | Sumitomo Chemical Co Ltd | Organic sulfur compound and its use for controlling harmful arthropod |
| DE102007032800A1 (en) | 2007-07-10 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Nonsteroidal progesterone receptor modulators |
| JP5558358B2 (en) | 2007-10-16 | 2014-07-23 | レプロス セラピューティクス インコーポレイティド | TRANS-clomiphene for metabolic syndrome |
| DE102007058747A1 (en) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nonsteroidal progesterone receptor modulators |
| EP2070941A1 (en) | 2007-12-14 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Stereoselective synthesis of selective estrogen receptor down-regulators |
| EP2070909A1 (en) | 2007-12-15 | 2009-06-17 | Bayer Schering Pharma AG | Non-steroidal progesterone receptor modulators |
| DE102008057230A1 (en) | 2008-11-11 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Synergistic pharmaceutical combination with an estrogen receptor antagonist and a progestin |
| JP5212350B2 (en) | 2008-12-24 | 2013-06-19 | 住友化学株式会社 | Halogen-containing organic sulfur compounds and uses thereof |
| EP2258375A1 (en) | 2009-06-04 | 2010-12-08 | Bayer Schering Pharma Aktiengesellschaft | 17B-alkyl-17alpha-oxy-estratrienes |
| DE102009034368A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases |
| DE102009034366A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-methyleneoxyalkylene aryl derivatives, process for their preparation and their use for the treatment of diseases |
| DE102009034367A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-benzylidene derivatives, process for their preparation and their use for the treatment of diseases |
| DE102009034362A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases |
| DE102009034526A1 (en) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-ethynylphenyl derivatives, process for their preparation and their use for the treatment of diseases |
| DE102009034525A1 (en) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| DE102010007719A1 (en) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesterone receptor antagonist |
| DE102010007722A1 (en) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesterone receptor antagonist |
| KR20130031339A (en) | 2010-06-16 | 2013-03-28 | 앙도르쉐르슈 인코포레이티드 | Methods of treating or preventing estrogen-related diseases |
| DE102010030538A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
| DE102011004899A1 (en) | 2011-03-01 | 2012-09-06 | Bayer Pharma Aktiengesellschaft | New 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl-derivatives are progesterone receptor antagonists useful to treat and prevent e.g. uterine fibroids, endometriosis, heavy menstrual bleeding and meningioma |
| DE102011087987A1 (en) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
| CA2865234A1 (en) | 2012-02-29 | 2013-09-06 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
| EP3932932A1 (en) | 2013-03-13 | 2022-01-05 | Sage Therapeutics, Inc. | Neuroactive steriods and methods of use thereof |
| HUE042368T2 (en) | 2013-04-11 | 2019-06-28 | Bayer Pharma AG | Progesterone receptor antagonist dosage form |
| JP6356218B2 (en) * | 2013-04-18 | 2018-07-11 | シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー．Ｘｉ’Ａｎ Ｌｉｂａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | Of 7-α- [9- (4,4,5,5,5-pentafluoropentylsulfinyl) nonyl] -estradi-1,3,5 (10) -triene-3,17β-diol having antitumor activity Ester derivatives and methods for their preparation |
| AU2016352592B2 (en) | 2015-11-10 | 2023-04-27 | Paracrine Therapeutics Ab | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen |
| AU2017240157B2 (en) | 2016-04-01 | 2022-10-20 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MD3481846T2 (en) | 2016-07-07 | 2021-11-30 | Sage Therapeutics Inc | 11-substituted 24-hydroxysterols for use in the treatment of NMDA related conditions |
| CA3038900A1 (en) | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
| AU2017345399B2 (en) | 2016-10-18 | 2022-02-24 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN115505019B (en) * | 2022-11-07 | 2024-01-26 | 南宁师范大学 | 7-amide substituted estrogenic compounds, and preparation method and application thereof |
| CN116041412A (en) * | 2023-01-13 | 2023-05-02 | 香港中文大学（深圳） | Fulvestrant derivative, preparation method and application thereof and medicine for treating breast cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
| DE3925507A1 (en) * | 1989-07-28 | 1991-01-31 | Schering Ag | 14,17 (ALPHA) ETHENO AND ETHANOESTRATRIA, METHOD FOR PRODUCING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICINAL PRODUCTS |
| DE4218743C2 (en) * | 1992-06-04 | 2001-10-25 | Schering Ag | Process for the preparation of C (7) -substituted Estra-1,3,5 (10) -trienes and new starting products for this process |
-
1996
- 1996-08-20 DE DE19635525A patent/DE19635525A1/en not_active Withdrawn
-
1997
- 1997-08-20 ZA ZA9707482A patent/ZA977482B/en unknown
- 1997-08-20 ES ES97943814T patent/ES2191857T3/en not_active Expired - Lifetime
- 1997-08-20 PL PL97331863A patent/PL186309B1/en not_active IP Right Cessation
- 1997-08-20 CZ CZ99579A patent/CZ57999A3/en unknown
- 1997-08-20 AU AU45520/97A patent/AU728843B2/en not_active Ceased
- 1997-08-20 SK SK188-99A patent/SK18899A3/en unknown
- 1997-08-20 AT AT97943814T patent/ATE231882T1/en not_active IP Right Cessation
- 1997-08-20 IL IL12860197A patent/IL128601A/en not_active IP Right Cessation
- 1997-08-20 BR BR9711328A patent/BR9711328A/en unknown
- 1997-08-20 KR KR1019997001396A patent/KR20000068261A/en not_active Application Discontinuation
- 1997-08-20 NZ NZ334277A patent/NZ334277A/en unknown
- 1997-08-20 TR TR1999/00432T patent/TR199900432T2/en unknown
- 1997-08-20 WO PCT/EP1997/004517 patent/WO1998007740A1/en not_active Application Discontinuation
- 1997-08-20 DK DK97943814T patent/DK0920441T3/en active
- 1997-08-20 EP EP97943814A patent/EP0920441B1/en not_active Expired - Lifetime
- 1997-08-20 DE DE59709239T patent/DE59709239D1/en not_active Expired - Fee Related
- 1997-08-20 JP JP10510412A patent/JP2001503024A/en not_active Ceased
- 1997-08-20 EE EEP199900075A patent/EE04021B1/en not_active IP Right Cessation
- 1997-08-20 AR ARP970103779A patent/AR009278A1/en not_active Application Discontinuation
- 1997-08-20 CA CA002263708A patent/CA2263708A1/en not_active Abandoned
- 1997-08-20 CN CN97198245A patent/CN1231670A/en active Pending
- 1997-08-20 EA EA199900210A patent/EA001577B1/en not_active IP Right Cessation
- 1997-08-20 PT PT97943814T patent/PT920441E/en unknown
- 1997-08-20 UA UA99031552A patent/UA50792C2/en unknown
- 1997-08-20 TW TW086111927A patent/TW552267B/en active
- 1997-08-20 HU HU9903106A patent/HUP9903106A3/en unknown
-
1999
- 1999-02-11 IS IS4976A patent/IS4976A/en unknown
- 1999-02-16 BG BG103185A patent/BG62972B1/en unknown
- 1999-02-19 NO NO19990793A patent/NO315655B1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG103185A (en) | 7 alpha -(epsilon -aminoalkyl)-estratrines, method for their preparation, pharmaceutical preparations containing them and their application for the preparation of medicamentous forms | |
| CO4340622A1 (en) | NEW BIS-INDOLIL MALEIMIDA MACROCYCLES | |
| NZ336302A (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia | |
| ATE513042T1 (en) | TUMOR-ASSOCIATED ANTIGEN DERIVATIVES OF THE MAGE FAMILY,NUCLIC ACID SEQUENCES ENCODING SAME FOR PRODUCING FUSION PROTEINS AND VACCINATION COMPOSITIONS | |
| AU649974B2 (en) | Photoprotection compositions having improved substantivity | |
| WO1997045137A8 (en) | Methods and compositions useful for inhibition of angiogenesis | |
| ATE51620T1 (en) | 3-(4-PIPERIDINYL)-1,2-BENZISOTHIAZOLE AND THEIR DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND USE AS MEDICINAL PRODUCTS. | |
| BR9806146A (en) | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing the same | |
| ATE354346T1 (en) | USE OF ALPHA-CEHC IN COSMETIC PREPARATIONS | |
| EP1008344A4 (en) | The new use of dicaffeoylquinic acid for treating hepatitis b and the diseases related with retrovirus, and the new caffeoylquinic acid derivatives | |
| DK0988302T3 (en) | benzonaphthyridines | |
| MD502G2 (en) | New adenozine derivatives, methods of obtainitg thereof, farmaceutical compositions on the base thereof | |
| NZ217959A (en) | Imidazoquinazoline derivatives and pharmaceutical compositions | |
| ATE119150T1 (en) | PIPERIDINE DERIVATIVES, THEIR PREPARATION AND USE. | |
| BR0005532A (en) | Substituted heterocyclic derivatives | |
| DE59407435D1 (en) | Cosmetic preparations containing 1-hydroxy-2-pyridones as anti-dandruff and deodorant agents | |
| EP0995430A3 (en) | Use of diacylolycerols for enhancing the barrier function of the skin | |
| DE69231883D1 (en) | 4- (1,1-dialkoxycarbonyl-alkyl) azetidin-2-one derivatives for the preparation of 4- (1-carboxy-alkyl) azetidin-2-one derivatives | |
| SE9404525D0 (en) | New uses of indolo- (3,2-b) -quinoxalines | |
| ATE258783T1 (en) | THERAPEUTIC AND COSMETIC AGENTS, THEIR USE AND PRODUCTION PROCESS | |
| BR9909869A (en) | Peroral compositions of controlled release of levosimendan | |
| AU2002218387A1 (en) | Cosmetic sunscreen compositions based on a synergic mixture of filters and uses | |
| MXPA02002007A (en) | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same. | |
| NZ246598A (en) | Trazodone derivatives; compounds and preparation, pharmaceutical compositions; intermediate compounds | |
| DE59401012D1 (en) | Cosmetic compositions containing organosiloxanes |